Lifeward Announces the Appointment of Mike Swinford to its Board of Directors
19 avr. 2024 08h30 HE
|
ReWalk Robotics Ltd. (DBA Lifeward)
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 19, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market lead...
Medicare Revises 2024 Fee Schedule to Include Payment Rate for the ReWalk Personal Exoskeleton
12 avr. 2024 08h30 HE
|
ReWalk Robotics Ltd. (DBA Lifeward)
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 12, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering...
Lifeward CEO Issues Open Letter to Shareholders on Progress to Finalize Exoskeleton Medicare Payment Rate
01 avr. 2024 16h30 HE
|
ReWalk Robotics Ltd. (DBA Lifeward)
Collaboration with CMS on final payment rate focuses on commercial transaction values for the latest generation of ReWalk Exoskeleton CMS indicates that recently issued fee schedule which omitted...
VA STAND Act introduced in the United States Senate
22 mars 2024 08h30 HE
|
ReWalk Robotics Ltd. (DBA Lifeward)
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader...
Lifeward Announces Reverse Share Split
13 mars 2024 11h45 HE
|
ReWalk Robotics Ltd. (DBA Lifeward)
Reverse split initiated to regain compliance with Nasdaq listing requirements Financial guidance for 2024 and profitability target for 2026 on existing capital remain unchanged ...
ReStore Exo-Suit Publications Demonstrate Improved Walking Outcomes Versus Conventional Stroke Therapy
08 mars 2024 08h30 HE
|
ReWalk Robotics Ltd. (DBA Lifeward)
Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving...
Lifeward announces the Centers for Medicare & Medicaid Services (“CMS”) is deferring its final decision on the payment rate for personal exoskeletons so that more recent claims information on the current, more advanced ReWalk Personal Exoskeleton may be considered
01 mars 2024 08h45 HE
|
ReWalk Robotics Ltd. (DBA Lifeward)
The decision was communicated through CMS’ bi-annual Healthcare Common Procedure Coding System (“HCPCS”) coding memorandum released yesterday; payment amount determination for ReWalk Personal...
Lifeward Reports Fourth Quarter and Full Year 2023 Financial Results
27 févr. 2024 08h00 HE
|
ReWalk Robotics Ltd. (DBA Lifeward)
Highest quarterly and annual revenue in the history of LifewardCommercial and operational integration complete; synergiesexpected to yield $3 million in annual net savings MARLBOROUGH, Mass. and...
Lifeward to Report Fourth Quarter and Fiscal Year-End 2023 Financial Results on February 27, 2024
20 févr. 2024 08h30 HE
|
ReWalk Robotics Ltd. (DBA Lifeward)
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader...
ReWalk Robotics Transforms Company Identity, Rebrands as Lifeward
29 janv. 2024 08h00 HE
|
ReWalk Robotics Ltd. (DBA Lifeward)
Lifeward brand reflects the Company’s commitment to pioneering innovative technology to empower the pursuit of life’s ambitions in the face of physical limitation or disability The complete...